Global neoantigen targeted therapies market size reached USD 1.76 billion in 2021 and is expected to register a revenue CAGR of 37.3% during the forecast period, according to latest analysis by Emergen Research.
Global neoantigen targeted therapies market size reached USD 1.76 billion in 2021 and is expected to register a revenue CAGR of 37.3% during the forecast period, according to latest analysis by Emergen Research. Pivotal role of neoantigens in cancer development and their unique structure that can be targeted by the immune system are major factors driving the market growth. Moreover, ongoing technological advancements in next-generation sequencing (NGS) platforms are further facilitating the identification of neoantigens.
For instance, in January 2021, Illumina, Inc. launched its next-generation sequencing platform, NovaSeq 6000, which is capable of generating up to 100 Gb of data per run. This will enable researchers to identify more neoantigens and help them develop targeted cancer therapies.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1034
Cancer immunotherapy is a promising treatment option with the potential to provide long-lasting remission. However, it has been observed that only a small percentage of patients respond to these therapies. The development of personalized neoantigen targeted therapies can help improve patient outcomes.
Side effects associated with these therapies, such as immune-related adverse events, are major restraints hampering the market growth. In addition, lack of reimbursement policies and high cost of treatment are other factors expected to challenge the market expansion over the forecast period.
The process of tumor formation and development is characterized by the accumulation of several genetic alterations that lead to uncontrolled cell proliferation. These genomic changes eventually result in the formation of new antigens, called neoantigens, on the surface of cancer cells. Neoantigens are unique to each individual and their tumor, making them ideal targets for cancer immunotherapy.
Neoantigen-targeted therapies are a new class of cancer immunotherapies that are designed to specifically target and destroy cancer cells by harnessing the power of the immune system. These therapies are highly personalized, as they are tailored to each individual patient’s tumor neoantigen profile.
Neoantigen-targeted therapies are still in the early stages of development, but they hold great promise as a potentially more effective and less toxic alternative to traditional cancer treatments such as chemotherapy and radiation therapy.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/neoantigen-targeted-therapies-market
Some Key Highlights from the Report
- Gynecological cancer segment revenue is expected to expand at a substantially rapid CAGR during the forecast period due to the rising prevalence of ovarian, uterine, and cervical cancer. According to World Health Organization (WHO), globally, approximately 13% of all new cancer cases and 14% of all cancer deaths in 2018 were due to gynecological cancers.
- Off-the-shelf neoantigen segment is expected to register a steady revenue growth rate over the forecast period due to the high efficacy of the therapiesThe off-the-shelf neoantigen segment is expected to register a steady revenue growth rate over the forecast period. This is attributed to the high efficacy of the therapies, which has resulted in their widespread adoption.
- North America held the largest revenue share in 2020 due to the presence of a large number of key players in the region and ongoing clinical trials for neoantigen targeted therapies. For instance, in September 2019, BioNTech SE initiated a pivotal Phase II clinical trial of its individualized neoantigen cancer vaccine, BNT162b2, in patients with metastatic non-small cell lung cancer (NSCLC).
- Some major companies in the global market report include BioNTech SE, Gritstone Bio, Inc., Genocea Biosciences, Moderna, Inc., Agenus, Inc., Immatics N.V., Advaxis, Inc., Precision Biologics, Inc., Gilead Sciences, Inc., Cellular Biomedicine Group, Inc., Achilles Therapeutics Plc, and Merck & Co., Inc.
- Key players in the market are focused on strategic initiatives to expand their product portfolio and strengthen their foothold in the global market. For instance, in September 2020, Freenome Inc. entered into a strategic collaboration with Janssen Pharmaceutical Companies of Johnson & Johnson to develop blood-based molecular diagnostics for early cancer detection. The partnership will enable Freenome to leverage Janssen’s expertise in oncology and expand its product portfolio.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1034
Emergen Research has segmented the global neoantigen targeted therapies market on the basis of target disease indication, neoantigen type, immunotherapy type, and region:
- Target Disease Indication Outlook (Revenue, USD Billion, 2019–2030)
- Colorectal Cancer
- Renal Cell Carcinoma
- Non-Small Cell Lung cancer
- Bone Cancer
- Gynecological Cancer
- Neoantigen Type Outlook (Revenue, USD Billion, 2019–2030)
- Personalized Neoantigen
- Off-the-shelf Neoantigen
- Immunotherapy Type Outlook (Revenue, USD Billion, 2019–2030)
- DNA/RNA-based Vaccines
- Protein-based Vaccines
- Dendritic Cell Vaccines
- TIL-based Therapies
- Regional Outlook (Revenue, USD Billion, 2019–2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/1034
Read Latest Articles Published by Emergen Research:
Prenatal Testing and Newborn Screening Market
Unmanned Ground Vehicle Market
Farm Management Software and Services Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-neoantigen-targeted-therapies-market